P S Masand1, A K Ashton, S Gupta, B Frank. 1. Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. givenss@upstate.edu
Abstract
OBJECTIVE: The authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs). METHOD:Thirty adults who had received SSRIs for at least 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greater than 19 out of a possible 30 on the Arizona Sexual Experience Scale were randomly assigned to receive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks. RESULTS: There were no significant differences between the sustained-release bupropion and placebo groups as measured by change in Arizona Sexual Experiences Scale or Hamilton Depression Rating Scale scores or side effects. CONCLUSIONS: Future studies should compare higher doses of bupropion for treating sexual dysfunction and should include a greater number of subjects.
RCT Entities:
OBJECTIVE: The authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs). METHOD: Thirty adults who had received SSRIs for at least 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greater than 19 out of a possible 30 on the Arizona Sexual Experience Scale were randomly assigned to receive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks. RESULTS: There were no significant differences between the sustained-release bupropion and placebo groups as measured by change in Arizona Sexual Experiences Scale or Hamilton Depression Rating Scale scores or side effects. CONCLUSIONS: Future studies should compare higher doses of bupropion for treating sexual dysfunction and should include a greater number of subjects.
Authors: Arne Møller; Valerie Voon; Casper Schmidt; Nikolina Skandali; Carsten Gleesborg; Timo L Kvamme; Hema Schmidt; Kim Frisch Journal: Neuropsychopharmacology Date: 2020-05-11 Impact factor: 7.853
Authors: Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin Journal: Prim Care Companion J Clin Psychiatry Date: 2004